FOLFOX6序贯周剂量多西紫杉醇及顺铂方案一线治疗老年晚期胃癌临床观察

Effect of FOLFOX6 sequential weekly doses of docetaxel and cisplatin in First-- line treatment of elderly patients with advanced gastric cancer

目的：观察FOLFOX6序贯周剂量多西紫杉醇及顺铀方案一线治疗老年晚期胃癌的疗效和安全性。方法：32例晚期胃癌患者先采用FOLFOX6方案化疗。14天为1个周期。FOLFOX6方案化疗3个周期结束后第14天开始给予多西紫杉醇＋顺铂方案化疗，每周给药一次，每4周为1周期，治疗2周期。结果：全组32例均可评价疗效，完全缓解0例（O％），部分缓解14例（43．8％），稳定13例（40．6％），进展5例（15．6％），总有效率为43.8％（14／32），临床获益率84．0％（27／32）。中住疾病进展时间为7．6个月（95％可信区间，3．6～12．12个月），中住生存期为10．9个月（95％可信区间，5．4～15．5个月），1年生存率为40．6％（13／32）。主要毒性反应为骨髓抑制、消化道反应和脱发，多数为1～2度。结论：FOLFOX6序贯周剂量多西紫杉醇及顺铂方案一线治疗老年晚期胃癌疗效较好，毒性反应较轻，耐受性好。

Objective： To observe the effect and safety of FOLFOX6 sequential weekly dose of docetaxel and cisplatin in first--line treatment of elderly patients with advanced gastric cancer. Methods：32 patients with advanced gastric cancer patients treated with FOLFOX6,14 days a cycle. The treatment with docetaxel and eisplatin chemotherapy started at 14 days after 3 cycles of FOLFOX6 chemotherapy,administered once a week, every 4 weeks for 1 cyele,fof 2 cycles of treatment. Results：The 32 eases can be evaluated,complete response 0 eases （0%） ,partial remission in 14 eases （43. 8%）, stable in 13 cases （40.6%） ,progress in 5 cases （15.6%）. Total effective rate was 43.8%（14/32） ,clinical benefit rate of 84.0% （27/32）. The median time to progression was 7.6 months （95% confidence interval,3.6 to 12.12 months） ,median survival was 10.9 months （95% confidence interval, 5.4 -- 15. 5 months）,1 --year survival rate 40. 6% （13/32）. Main toxicity was myelosuppression, gastrointestinal reactions and hair loss, mostly 1 to 2 degrees. Conclusion：FOLFOX6 sequential weekly doses of docetaxel and cisplatin in first--line treatment of elderly patients with advanccd gastric cancer is better,toxicity was mild and well tolerated.